Our data demonstrated that treatment with a small molecule elevates macroH2A2 levels and robustly activates viral mimicry responses in GBM cells, and the effect of this compound is largely abrogated by macroH2A2 knockdown. Here, MACROH2A2 is linked to glioblastoma.